James Kearse, MD
Family Medicine · Lugoff, SCNPI 1013969245
Payments from drug & device makers
Across 296 payments — averaging $13.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$616
- Amgen$359
- Boehringer Ingelheim$262
- Novo Nordisk$258
- Amarin Pharma, Inc.$255
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$251
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,90696%
- Education$1424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $616 |
| Amgen | 25 | $359 |
| Boehringer Ingelheim | 17 | $262 |
| Novo Nordisk | 18 | $258 |
| Amarin Pharma, Inc. | 19 | $255 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $251 |
| Astellas Pharma US Inc | 13 | $249 |
| GSK | 17 | $212 |
| AbbVie(2 entities) | 18 | $191 |
| Teva Pharmaceuticals USA, Inc. | 9 | $162 |
| Pfizer | 14 | $157 |
| Zyla Life Sciences, Inc. | 27 | $125 |
| Johnson & Johnson | 7 | $97 |
| Eisai Inc. | 7 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $93 |
| Kowa Pharmaceuticals America, Inc. | 6 | $82 |
| Lilly USA, LLC | 6 | $76 |
| Novartis | 4 | $63 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Optinose US, Inc. | 3 | $42 |
| Merck | 3 | $42 |
| Sanofi Pasteur Inc. | 3 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Insmed, Inc. | 2 | $28 |
| Aytu Biopharma, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| Shionogi Inc | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Medtronic | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Pulmonx Corporation | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Abbott | 1 | $12 |
How this compares
$4,048 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,646 | $376,422 |
| MounjaroTirzepatide | 158 | $205,165 |
| JardianceEmpagliflozin | 332 | $161,005 |
| FarxigaDapagliflozin Propanediol | 420 | $153,483 |
| TrulicityDulaglutide | 128 | $145,669 |
| XifaxanRifaximin | 41 | $106,953 |
| MyrbetriqMirabegron | 279 | $99,258 |
| LinzessLinaclotide | 148 | $98,988 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $87,054 |
| OzempicSemaglutide | 77 | $73,927 |
| XareltoRivaroxaban | 130 | $62,865 |
| NuplazidPimavanserin Tartrate | 11 | $58,645 |
| EntrestoSacubitril/Valsartan | 198 | $43,724 |
| JanuviaSitagliptin Phosphate | 89 | $36,831 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $26,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $157 | $387,4751,681 claims |
| Lilly USA, LLCMounjaro, Trulicity | $76 | $350,834286 claims |
| Boehringer IngelheimJardiance, Tradjenta | $262 | $174,403433 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $616 | $173,245451 claims |
| AbbVieLinzess, Creon, Vraylar | $191 | $143,645227 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $251 | $106,95341 claims |
| Astellas Pharma US IncMyrbetriq | $249 | $99,258279 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $212 | $95,071132 claims |
| Johnson & JohnsonXarelto, Invokana | $97 | $77,612186 claims |
| Novo NordiskOzempic | $258 | $73,92777 claims |
| Acadia Pharmaceuticals IncNuplazid | $14 | $58,64511 claims |
| NovartisEntresto | $63 | $43,724198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Lugoff
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.